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Expression and function of visfatin (Nampt), an
adipokine-enzyme involved in inflammatory
pathways of osteoarthritis
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Alain Sautet3, Claire Jacques1, Francis Berenbaum1,4,5* and Jérémie Sellam1,4,5
Abstract
Introduction: Visfatin is an adipokine that may be involved in intertissular joint communication in osteoarthritis
(OA). With a homodimeric conformation, it exerts nicotinamide phosphoribosyltransferase (Nampt) enzymatic
activity, essential for nicotinamide adenine dinucleotide biosynthesis. We examined the tissular origin and
conformation of visfatin/Nampt in human OA joints and investigated the role of visfatin/Nampt in chondrocytes
and osteoblasts by studying Nampt enzymatic activity.
Methods: Synovium, cartilage and subchondral bone from human OA joints were used for protein extraction or
incubated for 24 hours in serum-free media (conditioned media), and synovial fluid was obtained from OA patients.
Visfatin/Nampt expression in tissular extracts and conditioned media was evaluated by western blot and enzyme-linked
immunosorbent assay (ELISA), respectively. Nampt activity was assessed in OA synovium by colorimetric assay. Primary
cultures of murine chondrocytes and osteoblasts were stimulated with visfatin/Nampt and pretreated or not with
APO866, a pharmacologic inhibitor of Nampt activity. The effect on cytokines, chemokines, growth factors and
hypertrophic markers expression was examined by quantitative reverse transcriptase polymerase chain reaction
and/or ELISA.
Results: In tissular explants, conditioned media and synovial fluid, visfatin/Nampt was found as a homodimer,
corresponding to the enzymatically active conformation. All human OA joint tissues released visfatin/Nampt (synovium:
628 ± 106 ng/g tissue; subchondral bone: 195 ± 26 ng/g tissue; cartilage: 152 ± 46 ng/g tissue), with significantly higher
level for synovium (P <0.0005). Nampt activity was identified ex vivo in synovium. In vitro, visfatin/Nampt significantly
induced the expression of interleukin 6, keratinocyte chemoattractant and monocyte chemoattractant protein 1 in
chondrocytes and osteoblasts. APO866 decreased the mRNA and protein levels of these pro-inflammatory cytokines in
the two cell types (up to 94% and 63% inhibition, respectively). Levels of growth factors (vascular endothelial growth
factor, transforming growth factor β) and hypertrophic genes were unchanged with treatment.
Conclusion: Visfatin/Nampt is released by all human OA tissues in a dimeric enzymatically active conformation and
mostly by the synovium, which displays Nampt activity. The Nampt activity of visfatin is involved in chondrocyte and
osteoblast activation, so targeting this enzymatic activity to disrupt joint tissue interactions may be novel in OA
therapy.
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Introduction
Osteoarthritis (OA) is a chronic joint disease characterized
by cartilage breakdown, bone remodeling, osteophyte de-
velopment and synovium inflammation [1]. The synovial
membrane, which contains metabolically highly active
cells (that is, synoviocytes), is physiologically important
because it both nourishes chondrocytes via the synovial
fluid and joint space and removes metabolites and pro-
ducts of matrix degradation [2]. In OA, synovium is in-
flamed and characterized by hypertrophic and hyperplasic
synoviocytes and infiltrating mononuclear cells. All of
these cells produce interleukin (IL)-1β, IL-6, IL-8 and
tumor necrosis factor alpha (TNFα), major proinflam-
matory cytokines in OA [3,4]. This cytokinic environment
results in activated chondrocytes and subchondral osteo-
blasts that release prodegradative enzymes responsible for
joint disruption as well as proinflammatory cytokines and
chemokines such as IL-6, monocyte chemoattractant pro-
tein 1 (MCP-1), IL-8 or TNFα, thus perpetuating a vicious
inflammatory circle.
Recent data support a direct communication between
the subchondral bone and cartilage via a process of dif-
fusion through vessels, microcracks and fissures [5]. This
diffusion permits the exchange of soluble products with
the ability to modulate the activities of resident cells in
these tissues [6,7]. OA synovium may also be involved in
this pathological tissular network because it synthesizes
synovial fluid, releasing proinflammatory and prode-
gradative mediators participating in joint disruption. As
emphasized by Loeser and colleagues, we need to ad-
dress which of the factors released from synovium pro-
mote cartilage degradation and bone remodeling [1].
Among the soluble mediators released by synovium po-
tentially involved in OA pathophysiology, the so-called
adipokines, known as mediators mainly from adipose
tissue and found in biological fluids, may participate in
synovium–bone and synovium–cartilage interactions
[8-10]. Adipokines have pleiotropic effects and participate
in several metabolic, immune and inflammatory processes.
They contribute strikingly to the low-grade inflammatory
state observed in obese subjects and thus to the patho-
physiologic aspects of metabolic diseases as well as some
cancers. Among the adipokines, leptin and adiponectin
have been extensively studied in OA [11] and may be cru-
cial actors in the pathophysiologic features of the meta-
bolic OA phenotype [12].
Interest is growing in the adipokine visfatin, also called
pre-B-cell colony-enhancing factor [13] or nicotinamide
phosphoribosyltransferase (Nampt) [14]. This 52 kDa pro-
tein is constitutively synthesized by adipose tissue but also
by many other tissues, including synovium and cartilage
[15-17] and peripheral blood mononuclear cells [18],
which raises the issue of its strict definition as an adipo-
kine. Considering its various names, visfatin/Nampt/pre-
B-cell colony-enhancing factor is a complex adipokine
initially discovered as a molecule secreted by activated
lymphocytes in bone marrow and able to stimulate the
formation of pre-B cells [13]. Visfatin also acts as a pro-
inflammatory cytokine able to induce TNFα, IL-6 and
IL-1β [14,18].
Interestingly, visfatin is considered an adipokine-enzyme
with the name Nampt because it has Nampt enzymatic
activity due to a homodimeric conformation creating the
enzymatic active site, according to crystallographic struc-
ture study [19]. Visfatin/Nampt is involved in the bio-
synthetic pathway of nicotinamide adenine dinucleotide
(NAD) by converting nicotinamide into nicotinamide
mononucleotide, and represents the limiting factor of this
enzymatic reaction. NAD is an essential cofactor for many
intracellular processes: it allows the transfer of electrons
in redox reactions, modulates the activity of key regulators
in cell longevity and acts as a cofactor in DNA repair or
histone deacetylation [14,20]. This enzymatic activity can
be inhibited by a pharmacologic competitive inhibitor,
APO866 (also known as FK866 or WK175), which binds
to the active site formed by the dimer [21]. This inhibitor
greatly decreases the concentration of intracellular NAD,
thus resulting in apoptosis of tumoral cells in many cancer
types [22,23]. In contrast, in non-excess proliferating cells,
such as human monocytes, APO866 reduces the pro-
duction of inflammatory cytokines without affecting their
viability [24].
In rheumatoid arthritis, visfatin/Nampt is elevated in
plasma of patients [25] and may participate in the in-
flammatory process by orchestrating fibroblast motility
and by promoting cytokine synthesis [16,26]. Visfatin/
Nampt blockade with APO866 can prevent or limit joint
destruction and inflammation in collagen-induced arth-
ritis [24,27]. Conversely, little is known about visfatin/
Nampt in OA or its effects in chondrocytes and osteo-
blasts. We previously showed that visfatin/Nampt is pro-
duced by IL-1β-stimulated OA chondrocytes and may
induce a prodegradative and proinflammatory phenotype
of chondrocytes characterized by the induction of matrix
metalloproteinase (MMP)-3 and MMP-13 and synthesis
of prostaglandin E2 [17]. These activities could be medi-
ated in part by the insulin receptor signaling pathways,
as a recent study also showed an inhibition of the pro-
duction of proteoglycan induced by visfatin/Nampt via
this pathway [17,28,29]. However, the expression and
conformation of visfatin/Nampt within the OA joint and
the involvement of the enzymatic activity in visfatin/
Nampt-stimulated chondrocytes are poorly known. Fur-
thermore, the responsiveness of osteoblasts to visfatin/
Nampt still remains unknown.
In this study, we aimed to address the expression, con-
formation and enzymatic properties of visfatin/Nampt in
human OA joints, to decipher the proinflammatory role
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of this adipokine in two cell types involved in OA (that
is, chondrocytes and osteoblasts), and to connect the
cytokinic and enzymatic effects of this adipokine en-
zyme, investigating whether these effects are mediated
by Nampt activity.
Methods
Materials
All reagents were purchased from Sigma-Aldrich (Lyon,
France), unless stated otherwise. The human visfatin/
Nampt enzyme-linked immunosorbent assay (ELISA) kit
was from Adipogen (San Diego, CA, USA). New-born
Swiss mice were from Janvier (St Berthevin, France). The
anti-human visfatin/Nampt polyclonal antibody was from
Alexis (Paris, France). The immunoblot nitrocellulose
transfer membranes for western blot analysis were
from Whatman (Dassel, Germany). The western blot en-
hanced chemiluminescence system and kaleidoscope pres-
tained standards were from Bio-Rad (Marnes-la-Coquette,
France). The Cyclex visfatin/Nampt colorimetric assay kit
was from MBL International (Woburn, MA, USA). Re-
combinant mouse and human visfatin/Nampt (produced
in Escherichia coli with residual lipopolysaccharide con-
tamination <100 pg/ml according to the manufacturer)
was from Alexis Biochemicals (Paris, France). APO866, a
gift from Astellas Pharma (Munich, Germany), was pro-
vided by Alexander So (Rheumatology Department,
Centre Hospitalier Universitaire Vaudois and University of
Lausanne, Switzerland) and also purchased from Alexis
Biochemicals. IL-1β was from PeproTech (Rocky Hill, NJ,
USA).
Collection of osteoarthritis human material
Human OA knee explants and synovial fluids were ob-
tained from patients undergoing total joint replacement
surgery for OA at Saint-Antoine Hospital (Paris, France).
Informed consent for use of tissue was obtained from
each patient before surgery. The diagnosis of OA was
based on clinical and radiographic evaluations according
to the criteria of the American College of Rheumatology
[30]. All crude tissular explants were manually dissected
to obtain separate samples of each tissue type (that is,
cartilage, synovial membrane and subchondral bone).
The explants were cut into small pieces (~1 mm3),
washed several times with phosphate-buffered saline and
incubated in RPMI-1640 culture medium supplemented
with 100 U/ml penicillin, 100 μg/ml streptomycin, and 4
mM glutamine for 24 hours at 37°C. Conditioned media
(CM) were then collected, centrifuged (3,000 × g for 5
minutes) and stored at −80°C. Each volume of medium
was normalized to wet weight of explants (6 ml/g tissue),
as described previously [31].
In parallel, explants of each tissue type were frozen
and ground under liquid nitrogen using a pestle and
mortar. Protein was then extracted with lysing buffer for
western blot experiments. Experiments using human sam-
ples have been approved by a French Institutional Review
Board (Comité de Protection des Personnes Ile de France V).
Primary culture of murine articular chondrocytes
Mouse primary chondrocytes were isolated from articular
cartilage of 5-day-old to 6-day-old newborn Swiss mice as
described elsewhere [32]. After 1 week of amplification,
cells were incubated in serum-free Dulbecco’s modified
Eagle’s medium (DMEM) containing 0.1% of bovine
serum albumin for 24 hours before treatment.
Primary culture of murine osteoblasts
As described previously [33], mouse primary osteoblasts
were isolated from calvaria of 5-day-old to 6-day-old
newborn Swiss mice; the calvaria phenotype is consi-
dered close to that of subchondral bone [34]. Osteo-
blasts were cultured for 2 weeks in DMEM/HAM-F12
supplemented with 100 U/ml penicillin, 100 μg/ml
streptomycin, and 4 mM glutamine. In the first week,
cells were grown in DMEM/HAM-F12-PS-Glu enriched
with 10% serum and vitamin C (50 μg/ml). In the second
week, β-glycerol phosphate (5 mM) was added to the
same culture medium. Before treatment, cells were
weaned for 24 hours in a serum-free medium, DMEM/
HAM-F12-PS-Glu and 0.1% bovine serum albumin, and
treatments involved use of this same medium.
All experiments with murine articular chondrocytes and
osteoblasts were performed according to the protocols
approved by French and European ethics committees
(Comité Régional d’Ethique en Expérimentation Animale
N°3 de la région Ile de France).
Ex vivo assessment of human visfatin/Nampt by western
blot
Western blots were performed on protein extracts from
crude tissular explants, synovial fluids and CM. Crude tis-
sular explants were lysed in a buffer containing 20 mM
Tris–HCl (pH 7.6), 120 mM NaCl, 10 mM ethylene-
diamine tetraacetic acid pH 8, 10% glycerol, 1% Nonidet
P40, 10 mM sodium pyrophosphate and 1 protease inhibi-
tor cocktail (Roche Diagnostics, Indianapolis, IN, USA).
Proteins of all samples (45 μg tissular extracts, equal vo-
lume of CM reported to the tissue mass and 50 μg
synovial fluids) were then separated on Criterion XT 4 to
12% Bis–Tris Gel (Bio-Rad) and transferred to nitrocellu-
lose membranes. Monomeric and polymeric proteins were
detected by immunoblotting using specific polyclonal anti-
body (1/2,000) or a monoclonal antibody (1/2,000) against
human visfatin/Nampt (Enzo, Villeurbanne, France). Ampli-
fication of the signal was obtained using a secondary rabbit-
horseradish peroxidase (1/1,000) antibody anti-human IgG
(Paris Anticorps, Compiègne, France). Recombinant human
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visfatin/Nampt was used as positive control. The control of
proteins deposition was performed by quantification of total
protein of each sample using the Bio-Rad protein assay kit
(Bio-Rad, Munich, Germany) and staining of actin using an
anti-actin antibody (1/,2000; Sigma-Aldrich, Lyon, France)
(data not shown).
The monomeric form of visfatin/Nampt (that is, enzy-
matically inactive conformation) was investigated in
denaturing conditions and the polymeric form (that is,
enzymatically active conformation) was investigated in
nondenaturing conditions (without β-mercaptoethanol).
Results were revealed using an Immun-Star WesternC
Chemiluminescence Kit (Bio-Rad) and pictures were ob-
tained by MultiGauge version 3.0 (Fujifilm, Bois d’Arcy,
France).
Measurement of visfatin/Nampt enzymatic activity
To quantify the enzymatic activity of visfatin/Nampt in
OA human synovium, protein extracts from crude tissue
of three patients were assayed using the Cyclex Nampt
Colorimetric Assay Kit (MBL International). This assay
measures the kinetics of the production of NAD, the final
product of the visfatin/Nampt pathway. During this assay,
all components being in a saturated condition, the only
variation observed is exclusively linked to the concentra-
tion of visfatin/Nampt in the tissue extracts. Absorbance
of the derived product was read at 450 nm using a spec-
trophotometer. In order to confirm the specificity of the
assay, pretreatment by the specific inhibitor of Nampt,
APO866 (10 nM), was made by incubating the recom-
binant visfatin/Nampt and two other synovium samples
for 1 hour at 37°C. The curves were then drawn for the
absorbance (optical density) over time (minutes). The
initial Nampt enzymatic activity of each sample was thus
calculated as the slope of the curve and definitive results
were given per minute.
Treatment of primary cultures of chondrocytes and
osteoblasts
Confluent chondrocytes and osteoblasts were sti-
mulated with recombinant visfatin/Nampt (20, 50 and
100 nM) in serum-free medium for 24 hours. To assess
Nampt enzymatic activity, cells were pretreated for
4 hours with the Nampt inhibitor APO866 (10 nM) be-
fore the addition of visfatin/Nampt. The effect of 10 nM
APO866 on chondrocytes was considered efficient after
a dose–effect experiment under visfatin/Nampt stimu-
lation (data not shown) and previous results [28]. To
determine the optimal concentration of APO866 for
osteoblasts, cells underwent dose–effect experiments with
1, 10 and 100 nM APO866. The cytotoxic effects of
APO866 on cells were assayed using the Cytotoxicity
Detection Kit (lactate dehydrogenase; Roche, Mannheim,
Germany).
RNA extraction and quantitative real-time reverse
transcriptase-polymerase chain reaction
Total RNA was extracted from chondrocytes and osteo-
blasts using the RNeasy kit (Qiagen, Courtaboeuf, France)
and concentrations were determined using a spectro-
photometer (Eppendorf, Le Pecq, France). Reverse tran-
scription involved 500 ng total RNA with the Omniscript
RT kit (Qiagen). mRNA levels of IL-6, keratinocyte
chemoattractant (Kc; the murine equivalent of IL-8),
MCP-1, vascular endothelial growth factor, transforming
growth factor beta, runt-related transcription factor 2,
type X collagen and Indian hedgehog were quantified
using a Light Cycler LC480 (Roche Diagnostics) as de-
scribed previously [35]. Levels of mRNA were normalized
to those of murine hypoxanthine guanine phosphoribo-
syltransferase. Specific mouse primer sequences are re-
ferenced in Table S1 in Additional file 1.
ELISA assessment of visfatin/Nampt, IL-6, keratinocyte
chemoattractant and MCP-1 levels
The protein concentration of visfatin/Nampt released by
all OA joint tissues in CM was measured by ELISA kit
(AdipoGen, Liestal, Switzerland). The limit of detection
was 30 pg/ml. IL-6, Kc and MCP-1 concentrations were
measured in CM using the Quantikine ELISA kit (R&D
Systems, Lille, France). The limits of detection were 1.6,
2.0 and 2.0 pg/ml, respectively. The values were averages
of duplicate or triplicate tests.
Statistical analysis
All data are reported as mean ± standard error of the
mean. The Mann–Whitney test was used for analysis of
visfatin/Nampt in synovium and other tissues, and the
Wilcoxon test for analysis of the effect of visfatin/Nampt
and APO866 on chondrocytes and osteoblasts. Analyses
involved use of GraphPad Prism5 (GraphPad Software,
San Diego, CA, USA). P ≤ 0.05 was considered statisti-
cally significant.
Results
Visfatin/Nampt is mainly produced by OA synovium in
the human OA joint and is found in its enzymatically
active conformation
We examined the presence of visfatin/Nampt within hu-
man OA tissues and investigated whether tissular visfatin/
Nampt is found ex vivo in the dimeric conformation,
essential for its enzymatic activity. Visfatin/Nampt was
identified in all tissues and migrated as a 52 kDa band
under denaturing conditions (Figure 1), which cor-
responds to the molecular weight of the visfatin/Nampt
monomer. Under nondenaturing conditions, the 52 kDa
band intensity decreased and a major band appeared at
about 120 kDa due to visfatin/Nampt dimerization. More-
over, recombinant pure visfatin/Nampt showed a similar
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electrophoretic pattern. Similar results were obtained
using a monoclonal antibody against human visfatin/
Nampt confirming the specificity of the staining (data not
shown).
We next assessed the production of visfatin/Nampt
in CM by different OA tissues, first to determine the
secreted form of visfatin/Nampt (under denaturing and
nondenaturing conditions) and then visfatin/Nampt re-
lease. Western blot analysis under denaturing conditions
revealed the production of visfatin/Nampt by all OA
human joint tissues. Nondenaturing conditions allowed
identification of the dimeric conformation of the protein,
corresponding to its enzymatically active form (Figure 2A).
We have performed quantification of visfatin/Nampt in CM
using ELISA and have found that visfatin/Nampt was in-
deed released by all OA tissues (synovium, 628 ± 106 ng/g
tissue; subchondral bone, 195 ± 26 ng/g tissue; cartilage,
152 ± 46 ng/g tissue) (Figure 2B). Interestingly, the release
of visfatin/Nampt was significantly higher with synovial
membrane than cartilage (P = 0.0003) or subchondral
bone (P = 0.0012), with no difference between OA car-
tilage and subchondral bone (P = 0.08).
Since visfatin/Nampt was found to be mainly pro-
duced by the synovium, we investigated the presence of
the protein in OA synovial fluid. Again, under nondena-
turing conditions, visfatin/Nampt protein was present in
the dimeric conformation in synovial fluid (Figure 3).
Considering the synovial membrane as the most pro-
ductive tissue of visfatin/Nampt within the OA joint, we
assessed the enzymatic activity of visfatin/Nampt within
the synovium. By calculating the slope of the straight
curve corresponding to the production of nicotinamide
mononucleotide over time, we identified a detectable
Nampt activity in the synovium of three patients that was
in the same range as the recombinant visfatin/Nampt
(Figure 4). The use of the specific inhibitor APO866
decreased this enzymatic activity for the recombinant
visfatin/Nampt and for the two synovial membranes. The
inhibition for the synovial samples may be less effective in
this assay since the kit has been designed for purified pro-
tein but not for crude extracts.
Enzymatic visfatin/Nampt is involved in the
proinflammatory activation of murine chondrocytes
Because visfatin/Nampt was found in the dimeric form
ex vivo in human OA joints, we investigated the effect of
its enzymatic activity on chondrocyte activation. Murine
chondrocytes were stimulated with increasing concentra-
tions of visfatin/Nampt (20, 50 and 100 nM). We mea-
sured the mRNA expression of three major cytokines
involved in OA pathophysiologic features, IL-6, Kc and
MCP-1, to investigate visfatin/Nampt proinflammatory
effects. Visfatin/Nampt at the different doses stimulated
the mRNA expression of all three cytokines, with maximal
effect at 100 nM visfatin/Nampt (Figure 5). We chose
100 nM visfatin/Nampt for further experiments because it
produced the maximal increase in mRNA expression. The
visfatin/Nampt-mediated increase in mRNA levels for
IL-6, Kc and MCP-1 was 10.6-fold (P = 0.02), 4.9-fold
(P = 0.02) and 2.5-fold (P = 0.03), respectively, compared
with controls (Figure 6A) and was associated with an
increase in protein levels (P = 0.02) (5.8-fold, 29.7-fold and
10.5-fold, respectively, compared with unstimulated
controls) (Figure 6B). In contrast, visfatin/Nampt did not
stimulate vascular endothelial growth factor and trans-
forming growth factor beta nor the hypertrophic differen-
tiation markers Indian hedgehog, type X collagen and
runt-related transcription factor 2 (data not shown).
To determine the involvement of Nampt enzymatic
activity in these proinflammatory cytokinic effects, chon-
drocytes were pretreated with APO866 (10 nM) for
4 hours before visfatin/Nampt stimulation (100 nM).
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Figure 1 Intratissular expression of visfatin/Nampt from osteoarthritic human joint tissues. Human osteoarthritic joint tissues were obtained
after surgery, separated, frozen and ground to obtain protein extracts. Western blot analysis of the visfatin/nicotinamide phosphoribosyltransferase
(Nampt) protein level in tissues. Left panel: denaturing conditions, showing a monomeric conformation. Right panel: nondenaturing conditions,
showing polymeric conformation. Arrows show bands specific to visfatin/Nampt.
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This dose of APO866 was selected from our previous
work [28]. APO866 significantly decreased the mRNA
expression of IL-6, Kc and MCP-1 (P = 0.02) (inhibitory
effect of 94%, 83% and 62%, respectively, compared with
visfatin/Nampt alone; Figure 6A) and protein levels
(inhibition of 63%, 57% and 54% for IL-6, P = 0.02; Kc,
P = 0.03; and MCP-1, P = 0.02, respectively, compared
with visfatin/Nampt alone; Figure 6B).
The enzymatic activity of visfatin/Nampt is involved in
the proinflammatory activation of murine osteoblasts
To study the effect of visfatin/Nampt on osteoblasts, we
conducted similar experiments to those performed with
chondrocytes. Osteoblasts were stimulated with increasing
doses of recombinant visfatin/Nampt (20, 50 or 100 nM)
and the expression of IL-6, Kc and MCP-1 was measured
(Figure 7). The concentration of 100 nM was the
most efficient in stimulating osteoblasts for all mediators
(P = 0.06) and was thus chosen for all subsequent ex-
periments with osteoblasts. Visfatin/Nampt significantly
increased the mRNA expression of IL-6, Kc and MCP-1
(296-fold, P = 0.03; 262-fold, P = 0.02; and 161-fold,
P = 0.02, respectively, compared with the control;
Figure 8A) and protein levels (increase of 115-fold, P = 0.02;
164-fold, P = 0.02; and 22-fold, P = 0.03, respectively, com-
pared with the control; Figure 8B). Again, visfatin/Nampt
did not modify the expression of vascular endothelial
growth factor and transforming growth factor beta in osteo-
blasts (data not shown).
Before characterizing the role of the enzymatic activity
of visfatin/Nampt on osteoblasts, we determined the most
efficient dose of APO866 for Nampt blockade. Osteoblasts
were pretreated for 4 hours with 1, 10 or 100 nM
APO866 before stimulation with 100 nM visfatin/Nampt,
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Figure 2 Production of visfatin/Nampt by human osteoarthritic joint tissues. Human osteoarthritic joint tissues were incubated for 24 hours
in serum-free medium (6 ml/g tissue). Retrieved media were considered conditioned media. (A) Western blot analysis of visfatin/nicotinamide
phosphoribosyltransferase (Nampt) protein level in conditioned media. Left panel: denaturing conditions, showing monomeric conformation.
Right panel: nondenaturing conditions, showing dimeric conformation. Arrows show bands specific to visfatin/Nampt. (B) Enzyme-linked immunosorbent
assay of visfatin/Nampt released by cartilage (n= 15), synovial membrane (n= 13) and subchondral bone (n= 13). **P< 0.001, ***P< 0.0005. Horizontal
lines are medians. Each dot represents one sample.
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which could decrease the expression of IL-6, Kc and
MCP-1 (data not shown). APO866 at 10 and 100 nM
was the most efficient and we used the same concen-
tration of APO866 as for chondrocytes (10 nM). A cyto-
toxicity test measuring lactate dehydrogenase activity at
10 and 100 nM APO866 showed no severe mortality
(90% survival; data not shown).
Pretreating osteoblasts with APO866 thus significantly
decreased visfatin/Nampt-induced mRNA levels of IL-6,
Kc and MCP-1 (63% inhibition, P = 0.03; 86% inhibition,
P = 0.02; and 84% inhibition, P = 0.04, respectively, com-
pared with visfatin/Nampt alone; Figure 8A) and protein
levels (31% inhibition, P = 0.03; 35% inhibition, P = 0.07;
and 42% inhibition, P = 0.06, respectively, compared with
visfatin/Nampt alone; Figure 8B).
Discussion
In the present study we show that visfatin/Nampt is pro-
duced by the three main tissues of the human OA joint
but to a greater degree by synovium. Visfatin/Nampt is
naturally produced in a dimeric conformation by OA tis-
sues, which corresponds to its enzymatically active form.
Moreover, Nampt enzymatic activity is involved in the
proinflammatory effects of visfatin/Nampt on chondro-
cytes and osteoblasts.
The detection of visfatin/Nampt in OA tissues has been
reported previously, showing that all OA human tissues
expressed visfatin/Nampt (that is, cartilage, subchondral
bone, synovium as well as infrapatellar fat pad), but the
conformation was not assessed [36,37]. Interestingly,
Meier and colleagues detected visfatin/Nampt by immu-
nohistochemistry within OA synovium, especially around
vessels [26]. Here, we describe the conformation of
visfatin/Nampt produced by the joint and its enzymatic
activity. We previously reported that cultured human OA
chondrocytes express visfatin/Nampt in response to IL-1β
[17]. Here, we demonstrate that the three main tissues of
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Figure 3 Presence of visfatin/Nampt in synovial fluid. Synovial
fluids were obtained from four osteoarthritis patients with joint effusion.
Western blot analysis of visfatin/nicotinamide phosphoribosyltransferase
(Nampt) protein level under nondenaturing conditions, showing
polymeric conformation. Arrows show bands specific to visfatin/Nampt.
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Figure 4 Enzymatic activity of visfatin/Nampt in synovial membrane of human osteoarthritis. Enzymatic activity of visfatin/nicotinamide
phosphoribosyltransferase (Nampt) assayed in protein extracts of human osteoarthritis synovial membranes by colorimetric assay. Absorbance at
450 nm was measured every 5 minutes for 1 hour, representing the appearance of Nampt product, nicotinamide mononucleotide, over time. Negative
control, water; positive control, recombinant visfatin/Nampt (50 μg/ml). Data are mean ± standard error of the mean of 3 samples. In parallel,
recombinant visfatin/Nampt and two synovium samples were pretreated for 1 hour at 37°C with APO866 (10 nM). Histograms show the enzymatic
Nampt activity displayed by the sample (per minute), calculated from the slope of the straight line of the curve, which is obtained by representing the
absorbance (optical density) over time (per minute).
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Figure 5 Dose–response effect of visfatin/Nampt on the mRNA expression of interleukin-6 (IL-6), keratinocyte chemoattractant (Kc)
and monocyte chemoattractant protein 1 (MCP-1) by murine chondrocytes (from left to right). Murine chondrocytes were treated with
recombinant visfatin/nicotinamide phosphoribosyltransferase (Nampt) at 20, 50 and 100 nM for 24 hours. Quantitative reverse transcriptase-polymerase
chain reaction analysis of mRNA levels relative to that of murine hypoxanthine–guanine phosphoribosyltransferase. Data are mean ± standard error of
the mean of three experiments.
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Figure 6 Proinflammatory effect of visfatin/Nampt and effect of its enzymatic blockade by APO866 on murine chondrocytes. Murine
chondrocytes were pretreated or not with 10 nM APO866 for 4 hours, and then with 100 nM recombinant visfatin/nicotinamide phosphoribosyltransferase
(Nampt). (A) Quantitative reverse transcriptase-polymerase chain reaction analysis of mRNA levels of interleukin (IL)-6, keratinocyte chemoattractant (Kc)
and monocyte chemoattractant protein 1 (MCP-1) relative to that of hypoxanthine–guanine phosphoribosyltransferase, n = 6. (B) Enzyme-linked
immunosorbent assay of protein release of IL-6, Kc and MCP-1, n = 6. *P < 0.05 versus nonstimulated control; †P < 0.05 versus visfatin/Nampt
alone. The percentage corresponds to the average decrease of mRNA or protein level with APO866 pretreatment. Data are mean ± standard
error of the mean of six experiments.
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Figure 7 Dose–response effect of visfatin/Nampt on the mRNA expression of interleukin-6, keratinocyte chemoattractant and monocyte
chemoattractant protein 1 by murine osteoblasts. Murine osteoblasts were treated with recombinant visfatin/nicotinamide phosphoribosyltransferase
(Nampt) at 20, 50 and 100 nM for 24 hours. Quantitative reverse transcriptase-polymerase chain reaction analysis of mRNA levels of (left to right)
interleukin-6, keratinocyte chemoattractant and monocyte chemoattractant protein 1 relative to that of hypoxanthine–guanine phosphoribosyltransferase.
Data are mean ± standard error of the mean of four experiments.
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Figure 8 Proinflammatory effect of visfatin/Nampt and effect of its enzymatic blockade by APO866 on murine osteoblasts. Murine
osteoblasts were pretreated or not with 10 nM APO866 for 4 hours, and then with 100 nM recombinant visfatin/nicotinamide phosphoribosyltransferase
(Nampt). (A) Quantitative reverse transcriptase-polymerase chain reaction analysis of mRNA levels of interleukin (IL)-6, keratinocyte chemoattractant (Kc)
and monocyte chemoattractant protein 1 (MCP-1) relative to that of hypoxanthine–guanine phosphoribosyltransferase, n = 6. (B) Enzyme-linked
immunosorbent assay of protein release of IL-6, Kc and MCP-1, n = 6. *P < 0.05 versus nonstimulated control; †P < 0.05 versus visfatin/Nampt alone. The
percentage corresponds to the average decrease of mRNA or protein level with APO866 pretreatment. Data are mean ± standard error of the mean of
six experiments.
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the human OA joint (that is, cartilage, subchondral bone
and synovial membrane) store and release visfatin/Nampt,
which is more significantly produced by synovial mem-
brane than cartilage and subchondral bone. This finding
suggests a potential paracrine effect of visfatin/Nampt
from synovium to the other tissular and cellular compo-
nents of the joint. Similarly, other mediators such as
TNFα or IL-1β are released by the action of OA-activated
synovial membrane on adjacent cartilage and subchondral
bone tissues [2]. In agreement with Duan and colleagues,
visfatin/Nampt was present in synovial fluid from OA pa-
tients [38].
Visfatin/Nampt is a unique proinflammatory adipokine
because it displays both cytokinic and enzymatic activities,
the latter requiring a dimerization of two 52 kDa mono-
mers to organize the enzymatic active site capable of
converting nicotinamide to nicotinamide mononucleotide
[19,39]. We therefore investigated whether these dual
roles of visfatin/Nampt are linked and are involved in OA
pathophysiologic features. Use of nondenaturing condi-
tions revealed that visfatin/Nampt stored and released by
OA human tissues is naturally dimerized, because we de-
tected the 120 kDa form. This natural dimeric form has
been detected in human serum and is also constitutively
released by human hepatocytes [40,41].
Interestingly, visfatin/Nampt is also released by infra-
patellar fat pad: the role of such a release by this tissue
needs to be further addressed considering the intracap-
sular but extrasynovial localization of this tissue [37].
Because visfatin/Nampt came predominantly from the
synovium, we assessed and found that it had synovial en-
zymatic activity. We did not systematically find Nampt
activity in other OA joint tissues, probably because of
the lower amount of visfatin/Nampt stored in these tis-
sues (data not shown). We were not able to measure the
enzymatic activity in CM or synovial fluid because visfa-
tin/Nampt is much more diluted there than in tissues.
Furthermore, we could not discriminate which cell type
(that is, fibroblastic synoviocytes or infiltrating mono-
nuclear cells) showed Nampt activity in OA synovium.
Given the increased synovial production of visfatin/
Nampt in an enzymatically active form, we hypothesize
that visfatin/Nampt present in the OA joint originates
mainly from synovium and acts on adjacent cartilage
and subchondral bone in a paracrine pathway, with its
enzymatic activity involved in its cytokinic effect.
The effect of visfatin/Nampt on synovial fibroblasts
from patients with rheumatoid arthritis has been exten-
sively studied and is characterized by proinflammatory
and prodegradative effects (that is, IL-6, IL-8, MCP-1
and MMP release) [16,26,27]. Here, we investigated the
effects of visfatin/Nampt on chondrocytes and, for the
first time, on osteoblasts. Our team had demonstrated
that human OA chondrocytes stimulated by visfatin/
Nampt could acquire a prodegradative and proinflamma-
tory phenotype by increasing prostaglandin E2, MMP-3
and MMP-13 [17] Here, we further characterize the visfa-
tin/Nampt-induced proinflammatory phenotype of chon-
drocytes since visfatin/Nampt was also responsible for
stimulation of a cytokine (IL-6) and chemokines (Kc,
MCP-1), all mediators critical in the OA pathological
process because they participate in cartilage extracellular
matrix degradation and attraction of proinflammatory
cells [2,3]. Despite the ubiquitous proinflammatory effect
of visfatin and considering the ubiquitous role of Nampt
enzymatic activity, such effects remain selective because
we did not find any change in expression of growth factors
or hypertrophic differentiation markers. Busso and col-
leagues treated efficiently collagen-induced arthritic mice
with the specific enzymatic inhibitor APO866 and found
decreased expression of proinflammatory mediators
(IL-1β, IL-6 and MCP-1) but not other mediators (IL-10,
interferon-gamma, regulated upon activation normal
T-cell expressed and presumably secreted [RANTES], and
IL-12), which again illustrates the selective inhibitory ef-
fect of APO866 [18].
To determine the involvement of the enzymatic acti-
vity of visfatin/Nampt in these proinflammatory effects,
we pretreated chondrocytes and osteoblasts with the
inhibitor APO866 – which specifically antagonizes the
enzymatic activity only if the visfatin/Nampt dimerizes.
The induction of the proinflammatory cytokines was
greatly decreased (up to 94% and 63% for IL-6 in
chondrocytes and osteoblasts, respectively), which dem-
onstrates that the proinflammatory effects of visfatin/
Nampt on chondrocytes greatly depend on its enzymatic
activity. In agreement, we previously reported a similar
decrease in visfatin/Nampt-induced prostaglandin E2 re-
lease with APO866 treatment [28]. The inhibitory role of
APO866 seems to specifically antagonize the proinflam-
matory effects of recombinant visfatin/Nampt and is not
due to depletion of NAD (resulting in slower cellular func-
tion) or to inhibition of endogenous intracellular visfatin/
Nampt. Indeed, we stimulated chondrocytes with IL-1β
(0.1 ng/ml) treated with APO866 (10 nM) and found no
decrease in mRNA levels of IL-6, Kc or MCP-1 (data not
shown) while IL-1β is known to induce intracellular visfa-
tin/Nampt in chondrocytes [17]. In other conditions and
other cell types, extracellular visfatin/Nampt had similar
effects because it induced proinflammatory signaling in
human vascular smooth muscle cells through Nampt ac-
tivity, which was blocked by APO866 treatment [42].
We investigated the effects of visfatin/Nampt on mur-
ine osteoblasts for the first time. Osteoblasts were
sensitive to visfatin/Nampt because their stimulation in-
duced the expression and production of the same proin-
flammatory cytokines as in the chondrocyte experiments
(that is, IL-6, Kc and MCP-1). Interestingly, the induction
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of proinflammatory cytokines was much higher in osteo-
blasts than chondrocytes. As seen with chondrocytes, the
use of APO866 on osteoblasts decreased the production
of proinflammatory cytokines, which confirms the en-
zymatic effect of visfatin/Nampt on osteoblasts. Visfa-
tin/Nampt has a proinflammatory effect on the three
main cell types within the joint: chondrocytes, osteo-
blasts (depending in part on Nampt activity) and syno-
viocytes [16,26,27].
Conclusion
Visfatin/Nampt is produced and stored by all three major
tissues of the human OA joint, mainly synovial membrane,
under a dimeric conformation necessary to locally exert its
enzymatic action. Since this adipokine may activate chon-
drocytes but also osteoblasts and acts mainly by modulating
NAD synthesis, targeting specifically this Nampt enzymatic
activity with the oral compound APO866 may open new
therapeutic perspectives in OA.
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